Evaluation of semi-quantitative method for quantification of dopamine transporter in human PET study with 18F-FE-PE2I

Annals of Nuclear Medicine

Volumn 29, Issue 8, 2015, Pages 697-708

  Ikoma, Yoko ^a   Sasaki, Takeshi ^a   Kimura, Yasuyuki ^a   Seki, Chie ^a   Okubo, Yoshiro ^b   Suhara, Tetsuya ^a   Ito, Hiroshi ^a,c  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

18F FE PE2I; Binding potential; Occupancy; Positron emission tomography; Standardized uptake value ratio (SUVR)

Indexed keywords

DOPAMINE TRANSPORTER; N (3 IODOPROP ENYL) 2BETA CARBOFLUOROETHOXY 3BETA (4 METHYLPHENYL)NORTROPANE F 18; RADIOLIGAND; UNCLASSIFIED DRUG; (E)-N-(3-IODOPROP-2-ENYL)-2BETA-CARBOFLUOROETHOXY-3BETA-(4'-METHYL-PHENYL) NORTROPANE; NORTROPANE DERIVATIVE;

ADULT; ARTICLE; BRAIN BLOOD FLOW; CEREBELLUM; COMPUTER SIMULATION; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HUMAN; MALE; MOLECULAR IMAGING; NOISE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RADIOACTIVITY; SIMULATION; EVALUATION STUDY; METABOLISM; PROCEDURES; SIGNAL NOISE RATIO; YOUNG ADULT;

ADULT; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; NORTROPANES; POSITRON-EMISSION TOMOGRAPHY; SIGNAL-TO-NOISE RATIO; YOUNG ADULT;

EID: 84943353001     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-015-0993-3     Document Type: Article

References (26)

1. 18F]β-CFT in assessing disability in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1999;67(6):737–41.
2. Ginovart N, Lundin A, Farde L, Halldin C, Bäckman L, Swahn CG, et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington’s disease. Brain. 1997;120(3):503–14.
3. Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biol Psychiatry. 2005;57(3):229–38.
4. Arakawa R, Ichimiya T, Ito H, Takano A, Okumura M, Takahashi H, et al. Increase in thalamic binding of [11C]PE2I in patients with schizophrenia: a positron emission tomography study of dopamine transporter. J Psychiatr Res. 2009;43(15):1219–23.
5. 11C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. Eur J Nucl Med Mol Imaging. 2003;30(9):1220–30.
6. 18F]FE-PE2I, a new dopamine transporter PET radioligand. Synapse. 2009;63(10):871–80.
7. 11C]PE2I binding to the dopamine transporter in the human brain: a PET study. Eur J Nucl Med Mol Imaging. 2006;33(6):657–68.
8. 11C]PE2I: quantitative modeling and test-retest reproducibility. J Cereb Blood Flow Metab. 2008;28(5):1059–69.
9. 11C]PE2I and positron emission tomography. J Cereb Blood Flow Metab. 2009;29(7):1332–45.
10. 11C]PE2I and positron emission tomography: evaluation of reference tissue models. Ann Nucl Med. 2010;24(4):249–60.
11. 11C]PE2I. Eur J Nucl Med Mol Imaging. 2007;34(5):667–78.
12. 18F-FE-PE2I. J Nucl Med. 2011;52(1):132–9.
13. 18F-FE-PE2I. J Nucl Med. 2012;53(7):1065–73.
14. 11C]raclopride binding. J Cereb Blood Flow Metab. 1998;18(9):941–50.
15. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. NeuroImage. 1996;4(3 Pt 1):153–8.
16. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry. 1988;45(1):71–6.
17. Logan J, Fowler JS, Volkow ND, Ding YS, Wang GJ, Alexoff DL. A strategy for removing the bias in the graphical analysis method. J Cereb Blood Flow Metab. 2001;21(3):307–20.
18. 18F]FE-PE2I, a new probe for the dopamine transporter. Bioorg Med Chem Lett. 2009;19(16):4843–5.
19. Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Bioi Psychiatry. 1993;33(4):227–35.
20. 2 dopamine receptor occupancy in the living human brain: a PET study with risperidone. Psychopharmacology. 1993;110(3):265–72.
21. 11C]raclopride binding. J Cereb Blood Flow Metab. 1995;15:S643.
22. 11C-raclopride and positron emission tomography. Ann Neurol. 1992;31(2):184–92.
23. 2 receptor changes during the progression of early Parkinson’s disease. Mov Disord. 1993;8(2):134–8.
24. Volkow ND, Fowler JS, Wang GJ, Dewey SL, Schlyer D, MacGregor R, et al. Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. J Nucl Med. 1993;34(4):609–13.
25. 11C]raclopride studies. J Cereb Blood Flow Metab. 1996;16(1):42–52.
26. 2-dopamine receptors studied by PET–a comparison to the equilibrium analysis. J Cereb Blood Flow Metab. 1989;9(5):696–708.